https://www.selleckchem.com/products/hdm201.html
Background Although substantial evidence has shown that the mammalian target of rapamycin (mTOR) pathway is an important therapeutic target in gastric cancer, the overall response rates in patients to mTOR inhibitor everolimus have been less than initially expected. We hypothesized that the limited efficacy of everolimus in gastric cancer is due to the activation of extracellular signal-regulated kinase (ERK). Methods ERK activation was investigated using western blot. The effects of dual inhibition of ERK and mTOR via genetic and pharma
Like
Comment
Share
